Boron nitride nanotube-CREKA peptide as an effective target system to metastatic breast cancer
The development of nanomaterials that are capable of recognizing disease-specific biomarkers with high sensitivity and specificity is related to several advances in the field of nanomedicine. Furthermore, the targeted delivery of anticancer agents to tumor tissues enhances their efficiency and reduces their toxic side effects. Boron nitride nanotubes (BNNTs) are nanostructured materials, analog to carbon nanotubes, which present good biocompatibility and morphology suitable for tumor cell internalization. CREKA is a pentapeptide that has a high affinity to fibrin, a protein found in the new tumor vessels in the early stages of metastasis and in thrombosis regions.
In this study BNNTs were chemically functionalized with the peptide CREKA, and this system was characterized by Fourier transform infrared spectroscopy (FTIR), thermogravimetric analysis (TGA), zeta potential, scanning electron microscopy, and transmission electron microscopy.
After the mentioned chemical steps, the FTIR analysis shows an organic phase related to the CREKA, TGA indicates that about 10% of the peptide is firmly attached to BNNT surface. In addition, the radiolabeling process was successful, achieving the purity required for the biodistribution study. In vivo experiments showed that a considerable amount of BNNT-CREKA was accumulated at the tumor and metastasis sites.
The present results indicate an effective targeting of the system to tumor and metastasis sites. Further studies can reveal potential applications of functionalized BNNTs in cancer treatment.
KeywordsBNNT CREKA peptide 99mTc Nanomedicine Active target In vivo assay Metastasis
The authors would like to thank FAPEMIG (Fundação de Amparo à Pesquisa do Estado de Minas Gerais), CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), and CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico) for all financial support. ALBB, EMBS, JMR, LBF, THF and VNC acknowledge grants from CNPq. RSF and VMS acknowledge grants from CAPES. Experiments and analyses involving electron microscopy were performed in the Center of Microscopy at the Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil (http://www.microscopia.ufmg.br).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of Human and Animal Rights
The research was conducted in accordance with the ethical standards.
Ethical Approval and Informed Consent
All animal experimental protocols were approved by the Ethics Committee for Animal Experiments (CEUA) from Federal University of Minas Gerais under the protocol number 284/17 and comply with the requirements of the guide for the care and use of laboratory animals.
- Andrade GF, Soares DCF, dos Santos RG, Sousa EMB (2013) Mesoporous silica SBA-16 nanoparticles: synthesis, physicochemical characterization, release profile, and in vitro cytocompatibility studies. Microporous Mesoporous Mater 168:102–110. https://doi.org/10.1016/j.micromeso.2012.09.034 CrossRefGoogle Scholar
- Chan WC, White PD (2000) Fmoc solid phase peptide synthesisGoogle Scholar
- Chung EJ, Cheng Y, Morshed R et al (2014) Fibrin-binding, peptide amphiphile micelles for targeting glioblastoma. Biomaterials 35:1249–1256. https://doi.org/10.1016/j.biomaterials.2013.10.064 CrossRefPubMedPubMedCentralGoogle Scholar
- Ciofani G, Raffa V, Menciassi A, Cuschieri A (2008a) Cytocompatibility, interactions, and uptake of polyethyleneimine-coated boron nitride nanotubes by living cells: confirmation of their potential for biomedical applications. Biotechnol Bioeng 101:850–858. https://doi.org/10.1002/bit.21952 CrossRefPubMedGoogle Scholar
- Ciofani G, Raffa V, Menciassi A, Cuschieri A (2008b) Folate functionalized boron nitride nanotubes and their selective uptake by glioblastoma multiforme cells: implications for their use as boron carriers in clinical boron neutron capture therapy. Nanoscale Res Lett 4:113–121. https://doi.org/10.1007/s11671-008-9210-9 CrossRefPubMedPubMedCentralGoogle Scholar
- Fernandes RS, Silva JO, Mussi SV et al (2018) Nanostructured lipid carrier Co-loaded with doxorubicin and docosahexaenoic acid as a theranostic agent: evaluation of biodistribution and antitumor activity in experimental model. Mol Imaging Biol 20:437–447. https://doi.org/10.1007/s11307-017-1133-3 CrossRefPubMedPubMedCentralGoogle Scholar
- Lucky SS, Idris NM, Huang K et al (2016) In vivo biocompatibility, biodistribution and therapeutic efficiency of titania coated upconversion nanoparticles for photodynamic therapy of solid oral cancers. Theranostics 6:1844–1865. https://doi.org/10.7150/thno.15088 CrossRefPubMedPubMedCentralGoogle Scholar
- Soares DCF, Ferreira TH, Ferreira CDA et al (2011) Boron nitride nanotubes radiolabeled with (99m)Tc: preparation, physicochemical characterization, biodistribution study, and scintigraphic imaging in Swiss mice. Int J Pharm. https://doi.org/10.1016/j.ijpharm.2011.12.002 CrossRefPubMedGoogle Scholar
- Song Y, Huang Z, Xu J et al (2014) Multimodal SPION-CREKA peptide based agents for molecular imaging of microthrombus in a rat myocardial ischemia-reperfusion model. Biomaterials 35:2961–2970. https://doi.org/10.1016/j.biomaterials.2013.12.038 CrossRefPubMedGoogle Scholar
- Zhang B, Wang H, Shen S et al (2016) Fibrin-targeting peptide CREKA-conjugated multi-walled carbon nanotubes for self-amplified photothermal therapy of tumor. Biomaterials 79:46–55. https://doi.org/10.1016/j.biomaterials.2015.11.061 CrossRefPubMedGoogle Scholar
- Zhou Z, Wu X, Kresak A et al (2013) Peptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRI. Biomaterials 34:7683–7693. https://doi.org/10.1016/j.biomaterials.2013.06.057 CrossRefPubMedPubMedCentralGoogle Scholar